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ties were included as covariates. RESULTS: Following discharge
from initial hospitalization, the mean cost was $3755.28, the
mean number of outpatient visits was 4.14, and the mean
number of hospitalizations was 0.11 per two-month period, for
patients with post-MI HF. If these patients had not developed
HF, the estimated savings per 2-month interval was $1716, and
the estimated reduction in the number of visits and hospitaliza-
tions per 2-month interval was 30% and 50% respectively.
CONCLUSIONS: The development of HF in post-MI patients
results in a signiﬁcant increase in costs, outpatient visits and hos-
pitalizations as compared to post-MI patients without HF. The
cost of newer drugs that aim to delay or prevent the onset of
post-MI HF may be offset by savings in costs and resource uti-
lization attributable to HF in post-MI patients.
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OBJECTIVES: The Losartan Intervention for End Point Reduc-
tion in Hypertension (LIFE) study demonstrated a 13% relative
risk reduction in the primary composite endpoint (myocardial
infarction, stroke or death) and a 25% relative risk reduction in
stroke for patients treated with losartan compared to patients
treated with a ﬁrst-line antihypertensive agent (atenolol). Incor-
porating the results found in the LIFE study, an incremental cost-
effectiveness analysis was performed to determine the economic
feasibility of making losartan a ﬁrst line anti-hypertensive agent
in the prevention of cardiovascular morbidity and mortality.
METHODS: A Markov State Transition model was developed
to extrapolate the outcomes observed during the 4-year LIFE
trial to the patients’ lifetime. A comprehensive model was created
by drawing information from a number of sources within the 
literature, including other longitudinal cohort studies on patients
in the deﬁned health states. Considering a societal perspective,
fully allocated costs were calculated using the St. Paul’s Hospi-
tal Cost Model. QALY estimates for each of the given health
states were obtained from a variety of sources within the litera-
ture. Along with several univariate sensitivity analyses, extensive
probabilistic sensitivity analysis was performed in order to
examine the impact of a broad range of variation in our model
parameters. RESULTS: The incremental cost effectiveness ratio
of losartan versus atenolol was CDN$1337 (CDN$1 = US$0.78)
per QALY gained. This cost-effectiveness ratio was robust to
extensive sensitivity analysis, demonstrating a 95% probability
that the cost-effectiveness ratio would be less than CDN$20,000
per QALY gained. CONCLUSIONS: Losartan appears to be an
exciting, cost-effective alternative to traditional ﬁrst-line thera-
pies for hypertension. Results were robust to univariate and
probabilistic sensitivity analysis and are well within the accepted
ranges of cost-effectiveness ratios deemed to be efﬁcient and cost
effective.
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OBJECTIVE: To determine the cost-effectiveness of rosuvastatin
compared to ﬁve other statins, from a managed care payer per-
spective. METHODS: A decision-analytic model compared the
1-year costs and effectiveness of the following six statins, titrated
over the speciﬁed dose ranges in patients with elevated low-
density lipoprotein cholesterol (LDL): atorvastatin 10–80mg,
ﬂuvastatin 40–80mg, generic lovastatin 20–80mg, pravastatin
20–40mg, rosuvastatin 10–40mg, and simvastatin 20–80mg.
Effectiveness measures included percent change in LDL, high-
density lipoprotein cholesterol (HDL), and number of patients
achieving National Cholesterol Education Program (NCEP)
Second Adult Treatment Panel goal (per 10,000 treated). Effec-
tiveness estimates came from two 52-week, comparative clinical
trials and dose equivalence tables. Drug, physician and labora-
tory resource use were estimated using current NCEP guidelines,
then multiplied by Medicare reimbursement rates for services,
and wholesale acquisition costs for drugs. Probabilistic sensitiv-
ity analyses employed the net health beneﬁts framework 
and cost-effectiveness acceptability curves were constructed.
RESULTS: In the base-case analysis, rosuvastatin dominated
atorvastatin, lovastatin, pravastatin and simvastatin. Fluvastatin
was least costly but also least effective; rosuvastatin was most
effective and had the second lowest cost. Compared with ﬂu-
vastatin, the incremental LDL-C reduction, HDL-C increase, and
percent of patients to goal with rosuvastatin were 16%, 3%, and
27%, respectively. Incremental costs per additional 1% reduc-
tion in LDL-C, a 1% increase in HDL-C, and patient to goal
were $6, $33, and $353, respectively. Results were robust to
probabilistic analyses: in each of 1000 simulated populations of
1000 patients, rosuvastatin conferred more net health beneﬁts
than atorvastatin, lovastatin, pravastatin, or simvastatin. Rosu-
vastatin was the optimal choice among all statins when willing-
ness to pay for an additional 1% decrease in LDL, 1% increase
in HDL, and patient to goal exceeded $6, $37, and $353, respec-
tively. CONCLUSIONS: Rosuvastatin is less costly and more
effective than atorvastatin, lovastatin, pravastatin and simvas-
tatin; and highly cost-effective compared with ﬂuvastatin.
PCV19
GENDER AND STATIN THERAPY COST AND EFFICACY
Larsen TL, Smith DG
University of Michigan, Ann Arbor, MI, USA
OBJECTIVE: Coronary heart disease (CHD) is among the
leading causes of premature death in women. Cholesterol low-
ering therapies are beneﬁcial in primary and secondary preven-
tion of CHD. This study calculates the cost and efﬁcacy of
treating women with various HMGCoA reductase inhibitors
(statins). METHODS: Our analysis uses data from the Atorvas-
tatin Comparative Cholesterol Efﬁcacy and Safety Study
(ACCESS), a randomized, active-controlled, clinical trial. In
January 1999, 3273 patients completed the trial which had
assigned them to one of ﬁve study medications: atorvastatin
10–80mg/day; ﬂuvastatin 20–80mg/day; lovastatin 20–40
mg/day; pravastatin 20–40mg/day: or simvastatin 10–40mg/day.
We examined both costs of treatment to NCEP targets and 
efﬁcacy in achieving targets for men and women. Cost analyses
employed ordinary least squares regression and efﬁcacy analyses
employed logistic regression. RESULTS: In this study, we found
women to be $47 less costly to treat with lipid-lowering thera-
pies than men (95% CI: $US10-84), controlling for medication,
age, weight, race, blood pressure, baseline cholesterol level,
number of risk factors, diabetes, hypertension, and smoking
status. We found no difference in the likelihood of achieving
NCEP targets (odds ratio 0.984, 95% CI: 0.776–1.248), con-
trolling for the same factors as in the cost analysis. CONCLU-
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SIONS: While women were less costly to treat, this difference
was not attributable to medication efﬁcacy or observable patient
characteristics. Medication compliance may be a factor and
merits further investigation.
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Hypertension, a major risk factor for cardiovascular diseases
such as stroke and myocardial infarction, affects approximately
50 million adults in the United States. OBJECTIVES: To assess
utilization and costs for hypertension-related medical services
and pharmacotherapy among recipients in a state Medicaid pop-
ulation. METHODS: Medical services claims with a primary
ICD-9 CM diagnosis code for hypertension (401.xx) during cal-
endar year 2002, for recipients between 15 and 64 years of age
were extracted. Unique recipient identiﬁers obtained from these
claims were then used to extract hypertension-related prescrip-
tion claims. Medicaid reimbursements were used to calculate
costs for outpatient, ED and prescription use; Medicare DRG
average reimbursement amounts were used to calculate hospital
costs. RESULTS: Overall hypertension prevalence was 10.7%
among Medicaid recipients. Of the 17,610 recipients identiﬁed,
25% received single antihypertensive drug therapy, 60% received
two or more antihypertensive drugs and 15% had no prescrip-
tion claims for antihypertensive drugs. Of those recipients receiv-
ing single drug therapy (n = 4,478), 30% received angiotensin
converting enzyme inhibitors, 22% received beta blockers, 18%
received calcium channel blockers, 15% received diuretics, 10%
received angiotensin receptor blockers, and 5% received other
classes of drugs such as alpha1 blockers, centrally acting alpha2
agonists, and vasodilators. The rates of hospitalization, ED and
outpatient visits were 5/10,000 recipients, 43/10,000 recipients,
and 173/1000 recipients, respectively. The mean cost per hospi-
talization, ED and outpatient visit was $2422 (SD = $359), $188
(SD = $211) and $58 (SD = $61), respectively. Total hyperten-
sion-related expenditures to Medicaid were: $193,776 for hos-
pitalizations, $133,779 for ED use, $2,296,746 for outpatient
use and $6,744,515 for prescription drugs. CONCLUSIONS:
Results showed that a majority of recipients with hypertension
received two or more antihypertensive drugs. Hypertension is
responsible for a substantial economic burden to Medicaid with
outpatient use accounting for most medical visits and prescrip-
tion drugs accounting for most dollars.
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OBJECTIVES: To determine the rate in which patients treated
with statins received a concomitant potentially interacting 
medication (PIM) and the cost associated with receiving a PIM.
METHODS: New users of atorvastatin, pravastatin or simvas-
tatin during the time period 01.01.00–12.31.01 were selected
from a claims database for a large U.S. health plan. Adult sub-
jects were included if they had 24 months of continuous eligi-
bility surrounding their ﬁrst study medication claim, and had no
evidence of switching to another statin in the 12-month follow-
up period. To control for potential selection bias and confound-
ing by indication, two propensity score matching processes were
used. The ﬁrst matched subjects based on statin therapy and the
second matched subjects based on receipt of a PIM. Subjects
were followed for 12 months to measure total pharmacy and
medical utilization and cost. Logistic regression was used to
determine the risk of receiving a PIM and log-linear ordinary
least-squares regression was used to determine the cost differ-
ence. RESULTS: A total 48,958 subjects met the inclusion/
exclusion criteria. Of the 23,594 subjects who were matched on
statin therapy propensity scores, 30% of atorvastatin, 3% of
pravastatin and 32% of simvastatin subjects received a PIM in
the follow-up period. Relative to pravastatin, the odds ratios for
receiving a PIM (and 95%CI) were 15.3 (13.3–17.6) for ator-
vastatin and 16.3 (14.1–18.8) for simvastatin. 13,916 subjects
were matched on receipt of a PIM. Subjects receiving a PIM had
32% (p < 0.0001) greater medical and 50% (p < 0.0001) greater
pharmacy cost in the follow-up period than those that did not.
CONCLUSIONS: A signiﬁcant number of subjects receiving
atorvastatin or simvastatin also received a concomitant poten-
tially interacting medication. Subjects receiving PIMs were of sig-
niﬁcantly greater cost to the health care system. Opportunity
exists to educate providers and decision-makers regarding 
the prevalence and impact of potential statin medication 
interactions.
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OBJECTIVES: To assess direct (medical and drug) annual costs
and associated comorbidities of atrial ﬁbrillation (Aﬁb) in dif-
ferent patient age groups. METHODS: The study sample was
identiﬁed from an employer claims database including medical,
drug, and disability claims for approximately 2 million enrollees
over the period 1999–2002. Patients with at least two Aﬁb diag-
noses were included in the sample (n = 17,781). A non-Aﬁb
control sample was randomly selected with a 1 :1 ratio, with
patient characteristics (i.e. age, gender, region of residence)
matched to the Aﬁb sample. All patients were used in comor-
bidities analyses, while only those patients under age 65 (n =
3952) were used in cost analyses. Patients were stratiﬁed in two
age groups (<45, 45–64). To assess excess annual cost and
comorbidities, we compared Aﬁb patients to control patients.
Cost analyses were conducted from a third party payer’s 
perspective. All costs were adjusted to 2002 dollars using CPI.
Statistical signiﬁcance was measured by T-tests for cost compar-
isons, or Chi-square tests for comorbidities comparisons.
RESULTS: The average excess annual medical cost of an Aﬁb
patients was $12056 (P < 0.01). For patients in the older (45–64)
and younger (<45) age groups, the excess annual medical costs
of Aﬁb were $12,280 (P < 0.01) and $9969 (P < 0.01), respec-
tively. The difference between the excess costs for the two age
groups was not signiﬁcant. The most expensive cost component
of Aﬁb was inpatient hospitalization. Aﬁb was associated with
increased risk of atrial ﬂutter (Relative Risk (RR) = 140, P <
0.01), other arrhythmias/conduction disorders (RR = 7, P <
0.01), heart failure (RR = 8, P < 0.01), stroke (RR = 4, P < 0.01),
heart attack (RR = 4, P < 0.01), depressive disorders (RR = 2, P
< 0.01), and generalized anxiety disorder (RR = 2, P < 0.01).
CONCLUSIONS: The study found that Aﬁb is a costly disease
associated with high risk of heart attack, heart failure, stroke,
arrhythmias, depression, and generalized anxiety disorder. There
is no signiﬁcant cost difference across age groups.
